✦ LIBER ✦

PCN4 Decision-Analytic Model for the First-Line Therapy of Chronic Myeloid Leukemia

✍ Scribed by U. Rochau; G. Sroczynski; D. Wolf; S. Schmidt; A. Conrads-Frank; B. Jahn; K.R. Saverno; D. Brixner; G. Gastl; J. Radich; U. Siebert

Book ID: 119312148
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 58 KB
Volume: 15
Category: Article
ISSN: 1098-3015
DOI: 10.1016/j.jval.2012.08.1199

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Optimizing First-Line Therapy for Patien

Optimizing First-Line Therapy for Patients With Chronic Myeloid Leukemia

✍ Carmen Fava; Jorge Cortes 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 436 KB

First-line therapy for chronic myeloid l

First-line therapy for chronic myeloid leukemia: Past, present, and future

✍ Carolina Pavlovsky; Hagop Kantarjian; Jorge E. Cortes 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 326 KB

## Abstract The development of Bcr‐Abl tyrosine kinase inhibitors has dramatically changed the prognosis of patients with newly diagnosed chronic myeloid leukemia (CML). Standard‐dose imatinib (400 mg/day in chronic phase, 600 mg/day in advanced CML) now dominates the management of this disease, pr

PCN63 The Relative Value of Dasatinib Ve

PCN63 The Relative Value of Dasatinib Versus Imatinib as First-Line Treatment for Chronic Myeloid Leukemia

✍ L. Betegon; I. Gilloteau; P. Martin; A. Woolmore; I. Oyagüez 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

Dasatinib in the first-line treatment of

Dasatinib in the first-line treatment of chronic myeloid leukemia

✍ Patricia Ault 📂 Article 📅 2012 🏛 Frontline Medical Communications, Inc. 🌐 English ⚖ 264 KB

Six-year follow-up of patients receiving

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

✍ Hochhaus, A; O'Brien, S G; Guilhot, F; Druker, B J; Branford, S; Foroni, L; Gold 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 55 KB

Six-year follow-up of patients receiving

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

✍ Hochhaus, A; O'Brien, S G; Guilhot, F; Druker, B J; Branford, S; Foroni, L; Gold 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 608 KB